Risultati per: Nota 13 AIFA - Guida pratica

Avviso di sicurezza, ancora prescritti fuori da usi raccomandati

We read with interest the report on comparative risks of liver-related and cardiovascular disease (CVD) outcomes among lean and obese patients with non-alcoholic fatty liver disease (NAFLD) by Younes et al.1 Recently, international experts proposed redefining NAFLD as metabolic dysfunction-associated fatty liver disease (MAFLD).2 The impact of this name change on CVD risk prediction is not known. We performed a meta-analysis of observational cohort studies (by searching PubMed, Scopus and Web of Science from database inception to 30 June 2022) that simultaneously used the NAFLD and MAFLD definitions for examining the risk of incident CVD events associated with both definitions, among adults with and without either NAFLD or MAFLD, and in which hepatic steatosis was diagnosed by imaging techniques or blood biomarkers/scores. Studies using liver biopsy were not available. The primary outcomes were CVD mortality, non-fatal CVD events or both. Data from selected studies were…

Studio su oltre 10mila pazienti, il ritmo circadiano è determinante

Sarà attivato un tavolo di concertazione con ministeri e Regioni

New England Journal of Medicine, Volume 388, Issue 21, Page 1992-1999, May 2023.

Colpisce circa 600 persone in Italia, porta a dialisi o morte

Non portano benefici a lungo termine, ma possibili rischi